Novartis' Entresto Blockbuster Status On Track After CHMP Backing
This article was originally published in Scrip
Novartis' heart failure pill Entresto is already predicted to reach blockbuster status on the strength of its July approval in the US and now formal recommendation by CHMP in Europe for patients with reduced ejection fraction – representing some 50% of chronic heart failure patients - but those prospects could soar if an ongoing Phase III study presents the opportunity to eventually move the agent into the other half of chronic heart failure patients, those having preserved ejection fraction.
You may also be interested in...
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.
Macrophage Pharma’s lead asset will advance to clinical trials next year, making a series B financing round necessary, the UK biotech’s CEO tells Scrip.